Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million. The company completed the ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Nuvaxovid lasts six months under the same conditions. “The Novavax vaccine is much less demanding,” Fei Wen, a chemical engineer at the University of Michigan, told The Daily Beast.

Trade Name in the U.S. The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration (FDA). Authorized Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S.

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies.